CAR T Cell Therapy Market Summary
As per Market Research Future Analysis, the CAR T Cell Therapy Market was valued at 8 USD Billion in 2023 and is projected to grow to 45 USD Billion by 2035, reflecting a CAGR of 15.48% from 2025 to 2035. The market is driven by the increasing incidence of cancer globally, advancements in cellular therapy technology, and rising investments in biopharmaceutical research. The supportive regulatory environment further enhances the growth potential of CAR T therapies.
Key Market Trends & Highlights
Key trends driving the CAR T Cell Therapy Market include technological advancements and increasing collaboration in the biopharmaceutical sector.
- The CAR T Cell Therapy Market is expected to grow from 9.24 USD Billion in 2024 to 45 USD Billion by 2035.
- Oncology segment valued at 6.0 USD Billion in 2024, projected to reach 30.0 USD Billion by 2035.
- Global cancer cases projected to rise to over 29 million by 2040, increasing demand for CAR T therapies.
- North America held a market value of 5.0 USD Billion in 2024, leading the global market.
Market Size & Forecast
2023 Market Size | USD 8 Billion |
2024 Market Size | USD 9.24 Billion |
2035 Market Size | USD 45 Billion |
CAGR (2025-2035) | 15.48% |
Major Players
Key players include Pfizer, Intellia Therapeutics, Roche, Gilead Sciences, Celyad, Bristol Myers Squibb, Sangamo Therapeutics, Allogene Therapeutics, Celgene, Novartis, Bluebird Bio, Merck, AstraZeneca, Amgen, Juno Therapeutics.